<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7A19E252-D0A6-407D-8633-610CD5122E4A"><gtr:id>7A19E252-D0A6-407D-8633-610CD5122E4A</gtr:id><gtr:name>UCL School of Life and Medical Sciences</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Surgery</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name><gtr:address><gtr:line1>BBSRC</gtr:line1><gtr:line2>Polaris House</gtr:line2><gtr:line3>North Star Avenue</gtr:line3><gtr:line4>Swindon</gtr:line4><gtr:postCode>SN2 1UH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7A19E252-D0A6-407D-8633-610CD5122E4A"><gtr:id>7A19E252-D0A6-407D-8633-610CD5122E4A</gtr:id><gtr:name>UCL School of Life and Medical Sciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C04DE242-FC3C-4D5A-B576-037A94215D60"><gtr:id>C04DE242-FC3C-4D5A-B576-037A94215D60</gtr:id><gtr:firstName>Ludovic</gtr:firstName><gtr:surname>Vallier</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/78B6FA87-3745-4DC0-A3AA-40100F0B4637"><gtr:id>78B6FA87-3745-4DC0-A3AA-40100F0B4637</gtr:id><gtr:firstName>Anne</gtr:firstName><gtr:surname>Ferguson-Smith</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=TS%2FH001220%2F1"><gtr:id>9A8C7FEE-329F-440B-97D8-AEA495508C9F</gtr:id><gtr:title>Manufacturing solutions for high value induced pluripotent stem cell products (MS-iPS)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>TS/H001220/1</gtr:grantReference><gtr:abstractText>The project aims to develop the standards of practice and testing systems that will allow research on stem cells to be translated into the clinic. The primary focus is the use of induced pluripotent cells (iPS), but the project outputs are expected to be applicable to other types of cells, including embryonic stem cells (ES). The team will have the following roles within the project:1. To provide the cellular materials to enable assay development and cell testing2. To test the 'quality' of different cell populations i.e. their stability and differentiation potential3. To analyse the profile of gene expression of the cell populations4. To analyse the genetically imprinted regions in the cell populationsThe above approaches will allow the project members to correlate different cell characteristics with the regulation of specific genes, and/or genetic imprinting. With further development, these discoveries will form the basis of new assays and tests that are used in the production of therapeutically competent cells.</gtr:abstractText><gtr:fund><gtr:end>2013-03-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2010-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>653622</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>hIPSCs and Epigenetic</gtr:description><gtr:id>82890523-E5D4-4E96-ACDF-C371B95D290F</gtr:id><gtr:impact>Two publications are curentrly in preparation and we obatined a grant from the TSB to continue this work.</gtr:impact><gtr:partnerContribution>Develop new approach to characterise hIPSCs</gtr:partnerContribution><gtr:piContribution>The main objective of this colaboration is to define epigenetic variability among human induced pluripotent stem cells lines.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCL School of Life and Medical Sciences</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Cancer Institute</gtr:department><gtr:description>Collaboration with Epigenetic Experts</gtr:description><gtr:id>C8A43756-BE95-43C5-BD87-6A834E2E4A95</gtr:id><gtr:impact>1 publication</gtr:impact><gtr:partnerContribution>provide expertise for data analyses</gtr:partnerContribution><gtr:piContribution>This grant has brought together experts in stem cells and epigenetics allowing the development of novel projects and innovative science. To investigate new mechanisms of regulation, to access unique expertise and to develop more competitive project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>House of lord enquiry on regenerative medicine</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4B2E74A9-86DE-4AEF-9BF5-9A2E781D03E0</gtr:id><gtr:impact>NA / too soon

NA/ too soon</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>656986</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Manufacturing Solution for high value Induced pluripotent stem cells product</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Technology Strategy Board (TSB)</gtr:fundingOrg><gtr:id>FB71B869-67F6-47F3-971D-47F7F141CE9F</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>The aim of my group was to derive a panel of hIPSC lines from healthy individuals of different age and sex and then to characterise the capacity of the resulting lines to differentiate into the three germ layers endoderm, mesoderm and neuroectoderm. Accordingly, 45 hIPSCs lines were derived from 16 individuals 1 to 75 years old and with an equal representation of both Sex. In addition, we used two reprogramming methods (Sendai virus and Retrovirus) and different somatic cells (Skin fibroblast and vascular cells) to increase the complexity and deepness of our studies. 35 hIPSC lines were differentiated into the three germ layers and characterised by FACS, Q-PCR and immunostaining. These analyses revealed that hIPSC lines vary in their capacity of differentiation and that this variability is likely to be provoked by genetic background. We then provide large quantity of cells for epigenetic analyses to the different members of the consortium and then help them to interpret their results. We used these data to uncover new markers characterising hIPSC lines with a high capacity of differentiation toward specific germ layers. The importance of these markers was functionally validated by performing gain and loss of function experiments. These experiments revealed new mechanisms associating cell fate decisions and genetic.</gtr:description><gtr:exploitationPathways>Explotation plan for Manufacturing solutions for high value induced pluripotent stem cell (iPSC) products (MS-iPS).

The aim is to produce a minimum viable population-signature which can distinguish good from bad iPSCs in terms of differentiation capacity.

The analysis will group induced pluripotent cells derived from patient tissue samples in terms of their ability to differentiate into the three cell lineages (endoderm, mesoderm and ectoderm). It will determine the key epigenetic marks which are the most important distinguishing feature to be able to divide them into &amp;quot;good&amp;quot; (those which can fully differentiate) versus &amp;quot;bad&amp;quot; (those which can't) cell lines.
Initial epigenetic analysis has shown that non-CpG methylation appears to be a good discriminator, whereas CpG methylation appears not to be a good discriminator. Thus, the project will select and validate a key signature gene set in the existing cell lines. Further validation work will confirm the initial findings with the end result being the identification of a signature array which can be used as a tool.

Examples of the application of this signature could be: 
(i) Clonal analysis of revertants i.e bad cell lines which have been rescued to good ones.
(ii) Predictive capacity for cells from a completely different source/protocol but same differentiated lineages. 

The route to market will be via the licensing of patented gene sets for arrays. The types of products based on these innovations are well established and will initially be focussed on the non-clinical research market in the near term while pursuing clinical applications in the longer term.</gtr:exploitationPathways><gtr:id>11A3E75D-4FD7-464E-957E-E4274B5E0867</gtr:id><gtr:sectors><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>International consortium large scale hIPSCs project</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>CD4CE727-B6F7-4D0D-B0C5-64455B2FF882</gtr:id><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have identified a new type of endodermal stem cells.</gtr:description><gtr:id>E0D2B539-14C7-4527-B8CA-60E3E2AF7176</gtr:id><gtr:impact>These cells could enable the production of homogenous population of pancreatic, lung, and hepatic cells from a broad number of hPSCs.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Foregut Stem Cells</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AD8A33C5-BDC7-409D-9047-75B56FB89AA4"><gtr:id>AD8A33C5-BDC7-409D-9047-75B56FB89AA4</gtr:id><gtr:title>Non-CG DNA methylation is a biomarker for assessing endodermal differentiation capacity in pluripotent stem cells.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fdb4ff287270e26a1be8ad51e5106b2b"><gtr:id>fdb4ff287270e26a1be8ad51e5106b2b</gtr:id><gtr:otherNames>Butcher LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3D4083EF-0BD3-46A1-981A-A6202FEB5317"><gtr:id>3D4083EF-0BD3-46A1-981A-A6202FEB5317</gtr:id><gtr:title>Genetic background drives transcriptional variation in human induced pluripotent stem cells.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/442a496d5dc0d21b90eedf42d844ff87"><gtr:id>442a496d5dc0d21b90eedf42d844ff87</gtr:id><gtr:otherNames>Rouhani F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">TS/H001220/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>99E0B904-CAB5-4511-AFB3-AA6D2B171F97</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Process engineering</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>9C387DA5-CD5F-43E4-AA74-82CBF4DB6617</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Bioprocess Engineering</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>195B48B4-2BC5-4DEB-BA1A-323A90D8730D</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Tissue engineering</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>